FAQ

Multiple Sclerosis, Relapsing-Remitting

Known as: Remitting Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Remitting-Relapsing 
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial… (More)

Topic mentions per year

Topic mentions per year

1978-2017
010020030019782017

Related topics

Related topics

9 relations
GlatiramerIn BloodMicrobiologicalMyelitis, Transverse
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Multiple Sclerosis, Relapsing-Remitting
radiotherapeutic
prevention & control
Microbiological
nursing therapy
chemically induced

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
BACKGROUND BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
BACKGROUND Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes… (More)
  • figure 1
  • table 1
  • figure 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
BACKGROUND Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes… (More)
  • figure 1
  • table 1
  • figure 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
BACKGROUND There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may… (More)
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
A 46-year-old woman with relapsing-remitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PML) after… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Oral simvastatin treatment in relapsing-remitting multiple sclerosis.
Many drugs have been approved for relapsing forms of multiple sclerosis but are only partly effective, are injected, and are… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Brain atrophy in clinically early relapsing-remitting multiple sclerosis.
Brain atrophy measured by MRI is a potentially useful tool for monitoring disease progression in multiple sclerosis. The location… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.
It has been difficult to establish a strong correlation between total brain T2-weighted lesion volume on MRI and clinical… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple…
We studied copolymer 1 (Copaxone) in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple… (More)
Is this relevant?